AquaCelle (Microencapsulation technology)

AquaCelle is a patented microencapsulation technology that encases lipophilic compounds such as omega-3 fatty acids and CoQ10 within self-emulsifying lipid matrices to dramatically enhance their gastrointestinal absorption. By forming stable nanoemulsions upon contact with digestive fluids, AquaCelle bypasses the solubility limitations that typically restrict absorption of fat-soluble nutrients.

Origin & History

AquaCelle is a patented self-micro-emulsifying drug delivery system (SMEDS/SEDDS) developed in Australia by Pharmako Biotechnologies. It is a synthetically formulated lipid-based technology using pharmacopoeial-grade ingredients that self-assembles into micelles in aqueous environments to enhance absorption of lipophilic compounds.

Historical & Cultural Context

No historical or traditional medicinal use exists for AquaCelle, as it is a modern pharmaceutical technology. It was developed as a contemporary solution to address poor bioavailability of lipophilic nutrients and supplements.

Health Benefits

• Enhanced omega-3 absorption by 7.1-fold (AUC) and 3.7-fold (Cmax) compared to standard forms (one RCT, moderate evidence)
• Improved CoQ10 bioavailability with superior absorption versus standard ubiquinone extract (preliminary evidence from pharmacokinetic study)
• Reduced fishy reflux from omega-3 supplements through improved solubility (observational evidence)
• Enables effective nutrient absorption without requiring high-fat meals (mechanistic evidence)
• Allows for smaller supplement doses due to enhanced bioavailability (based on 85:15 active-to-carrier ratio)

How It Works

AquaCelle employs a self-microemulsifying drug delivery system (SMEDDS) in which lipophilic actives are encapsulated within a glyceride-based lipid matrix that spontaneously forms nanoscale emulsion droplets (typically 100–300 nm) upon exposure to aqueous gastrointestinal fluid. These nanosized droplets dramatically increase the surface area available for pancreatic lipase hydrolysis and facilitate incorporation of fatty acids and fat-soluble compounds into mixed micelles alongside bile salts, enabling efficient uptake via intestinal enterocyte transporters including fatty acid translocase (CD36) and NPC1L1. The encapsulation also protects sensitive compounds such as EPA and DHA from oxidative degradation in the gut lumen, further preserving their bioactive integrity prior to absorption.

Scientific Research

A randomized, double-blind pharmacokinetic study (PMID: 31637467) demonstrated that AquaCelle increased omega-3 absorption 7.1-fold (AUC0-24h) in healthy subjects taking 680 mg omega-3 ethyl esters under low-fat conditions. Another pharmacokinetic study showed superior CoQ10 absorption with smaller micelle formation, though specific sample sizes were not detailed.

Clinical Summary

A randomized crossover pharmacokinetic trial demonstrated that AquaCelle-encapsulated omega-3 achieved a 7.1-fold increase in area under the curve (AUC) and a 3.7-fold increase in peak plasma concentration (Cmax) compared to standard triglyceride-form fish oil, representing moderate-quality evidence from a single RCT. A separate pharmacokinetic study found that CoQ10 delivered via AquaCelle exhibited superior plasma absorption relative to standard ubiquinone extract, though this remains preliminary given the limited study design and small sample size. The omega-3 formulation also demonstrated a clinically meaningful reduction in fishy reflux compared to conventional fish oil capsules, suggesting improved patient tolerability. Overall, the evidence base is promising but still early-stage, with larger, independent RCTs needed to confirm these findings across diverse populations and additional lipophilic compounds.

Nutritional Profile

AquaCelle is a delivery technology platform rather than a nutrient itself, containing no intrinsic macronutrients, micronutrients, or caloric value. The system is composed of a self-emulsifying microencapsulation matrix (lipid-based excipients including medium-chain triglycerides and emulsifiers such as polysorbate or lecithin derivatives) designed to encapsulate lipophilic actives. The technology forms micelle-like structures (particle size typically in the nanometer-to-micron range) upon contact with aqueous environments in the GI tract. Key functional components include: (1) amphiphilic lipid carriers that spontaneously emulsify in gastric/intestinal fluid, (2) hydrophilic outer shell enabling water dispersibility of otherwise poorly soluble compounds. When loaded with omega-3 fatty acids (EPA/DHA), bioavailability is enhanced 7.1-fold by AUC and 3.7-fold by Cmax versus standard triglyceride fish oil forms per one RCT. When loaded with CoQ10 (ubiquinol or ubiquinone), superior pharmacokinetic absorption is observed versus standard ubiquinone extract in preliminary studies. The matrix itself contributes negligible macronutrient content per typical dose. Bioavailability enhancement is the sole nutritional relevance — effective nutrient absorption is achieved even in low-fat meal conditions, addressing the fat-dependent absorption limitation common to lipophilic nutrients. No fiber, protein, vitamins, or minerals are inherent to the delivery matrix itself.

Preparation & Dosage

Clinically studied at 680 mg omega-3 ethyl esters (272 mg EPA + 204 mg DHA) with AquaCelle at an 85:15 active-to-AquaCelle ratio. For CoQ10, specific dosages were not detailed in available studies. AquaCelle is typically formulated at 85% active ingredient to 15% carrier. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Omega-3 fatty acids, Coenzyme Q10, Resveratrol, Astaxanthin, Lutein

Safety & Interactions

AquaCelle-based supplements share the general safety profile of their encapsulated actives, such as omega-3 fatty acids and CoQ10, with the microencapsulation excipients (primarily food-grade glycerides and emulsifiers) considered Generally Recognized As Safe (GRAS) at typical dietary doses. High-dose omega-3 formulations delivered via AquaCelle may potentiate the anticoagulant effects of warfarin, aspirin, or other antiplatelet agents due to enhanced EPA and DHA absorption, warranting caution and INR monitoring. CoQ10 delivered in AquaCelle may modestly reduce the efficacy of warfarin by antagonizing vitamin K-dependent clotting pathways, and patients on statin therapy should consult a physician before use. Pregnancy and lactation safety has not been specifically studied for the AquaCelle delivery system itself; while omega-3 supplementation is generally considered safe in pregnancy, the enhanced absorption magnitude of AquaCelle formulations means dose adjustments and physician oversight are advisable.